Pediatrix reaffirms $280–$300 million EBITDA outlook

• Pediatrix said its second-quarter payor mix remained stable despite unfavorable shifts reported elsewhere in healthcare.
• Pediatrix shares fell 7.7% to $24.11 in premarket trading following the business update.
• The company maintained its 2026 Adjusted EBITDA outlook of $280–$300 million.

Pediatrix Medical Group (NYSE:MD) said its second-quarter payor mix remained stable and reaffirmed its $280–$300 million 2026 Adjusted EBITDA outlook.

The update followed reports from other healthcare companies of changing utilization and reimbursement trends, which raised concerns about industry revenue pressure.

Pediatrix said its payor mix matched recent historical trends and internal expectations, with no unfavorable shift experienced during the quarter.

The company also reported no material change in other net revenue trends and will publish full results before markets open on August 4.

Pediatrix reported Q1 revenue of $476.2 million and adjusted EBITDA of $58.2 million, while commercial payor exposure increased 45 basis points.

The physician-services group provides obstetric, neonatal and pediatric care through about 4,300 affiliated clinicians across hospital and office settings.